Highly significant positive top-line results from a Phase III pivotal trial for SP 102 to treat sciatica.- Scilex Holding Company.
Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announces highly significant positive top-line results from its Phase III SP-102 (Semdexa) Pivotal Trial C.L.E.A.R Program for its novel, non-opioid, corticosteroid formulation, injectable dexamethasone sodium phosphate viscous gel product for the treatment of lumbosacral radicular pain (sciatica).